Ivermectin, a widely used drug with a favorable safety profile, is thought to act at different protein-binding sites to reduce viral replication. The study aims to investigate the effect of ivermectin on the duration of symptoms in adults with mild COVID-19. Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for the treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.